Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The March 2005 monograph topics are ziconotide, eszopiclone, palifermin, paclitaxel, and darifenacin. The DUE is on eszopiclone.
De BroeM.E., D'HaeseP.C.Improving outcomes in hyperphosphatemia.Nephrol Dial Transplant.2004; 19(suppl 1): i14–i18.
3.
DewberryK.Lanthanum carbonate: A novel non-calcium containing phosphate binder [abstract].J Am Soc Nephrol.1997; 8(suppl): 560A(A2610).
4.
DeBroeM.D.Lanthanum carbonate (Fosrenol): A new agent in the treatment of hyperphosphataemia in end-stage renal failure. Poster presented at: IV Symposium on Advances in Renal Osteodystrophy; June 7, 2002; Oviedo, Spain.
5.
DammentS.J.P., TottenW.The pharmacology of a new phosphate binder, lanthanum carbonate. Abstract presented at: 40th ERA-EDTA World Congress of Nephrology; June 8-12, 2003; Berlin, Germany.
GraffL., BurnelD.A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption.Res Commun Mol Pathol Pharmacol.1995; 89: 373–388.
8.
EmmettM.A comparison of clinically useful phosphorus binders for patients with chronic kidney failure.Kidney Int.2004; 66(suppl 1): S25–S32.
9.
JoyM.S.Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients. Abstract A1327 presented at: Annual Meeting of the American Society of Nephrology; November 1999; Miami, FL.
10.
JoyM.S.Safety profile of lanthanum carbonate in hemodialysis patients: results from a Phase III U.S. study. Abstract A1997 presented at: Annual Meeting of the American Society of Nephrology; October 15, 2001; San Francisco, CA.
11.
StewartJ., FiddlerG., WebsterI.Lanthanum carbonate (Fosrenol), a novel, non-calcium, non-aluminum phosphate binder, is well tolerated when given with or after food. Abstract presented at: 9th Asian Pacific Congress of Nephrology; February 16-20, 2003; Pattaya, Thailand.
12.
FiddlerG., TanakaT.Low systemic absorption and excellent tolerability during administration of lanthanum carbonate (Fosrenol) for 5 days. Abstract presented at: 9th Asian Pacific Congress of Nephrology; February 16-20, 2003; Pattaya, Thailand.
13.
StewartJ., FrazerN.Administration of a novel phosphate binder, Fosrenol, with food is associated with good tolerability and low systemic absorption. Abstract presented at: Annual Meeting of the American Society of Nephrology; November 1-4, 2002; Philadelphia, PA.
14.
DammentS.J.P., GillM., ConferS., JonesC., PennickM., WebsterI.The bone kinetics of lanthanum in dialysis patients treated with lanthanum carbonate for up to 4.5 years. Abstract F-PO948 presented at: Annual Meeting of the American Society of Nephrology; October 27 – November 1, 2004; St. Louis, MO.
15.
MallucheH.H., FaugereM-C, WangG., DammentS.J.P., WebsterI.No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. Abstract F-PO944 presented at: Annual Meeting of the American Society of Nephrology; October 27 – November 1, 2004; St. Louis, MO.
16.
MallucheH.H., FaugereM-C, WangG., FinnW.F.Lanthanum carbonate and bone: No adverse effects observed after 1 year of treatment in a randomized, comparator-controlled trial. Abstract F-PO945 presented at: Annual Meeting of the American Society of Nephrology; October 27 – November 1, 2004; St. Louis, MO.
17.
HutchisonA.J., SpeakeM., Al-BaajF.Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.Nephrol Dial Transplant.2004; 19: 1902–1906.
18.
FinnW.F.Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. Abstract presented at: Annual Meeting of the American Society of Nephrology; November 1999; Miami, FL.
19.
FinnW.F., JoyM.S., HladikG; Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.Clin Nephrol.2004; 62: 193–201.
20.
JoyM.S.Results of a randomized, Phase III, dose-titration, parallel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis patients. Abstract A1996 presented at: Annual Meeting of the American Society of Nephrology; October 15, 2001; San Francisco, CA.
21.
JoyM.S., FinnWF; AM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.Am J Kidney Dis.2003; 42: 96–107.
22.
FinnW.F., JoyM.S.Efficacy and safety of long-term treatment with lanthanum carbonate – a novel phosphate-binding agent. Abstract presented at: National Kidney Foundation Clinical Meeting; April 2-6, 2003; Dallas, TX.
23.
D'HaeseP.C., SpasovskiG.B., SikoleA.A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.Kidney Int.2003; 63(suppl 1): S73–S78.
24.
HutchisonA.J.Lanthanum carbonate (Fosrenol), a novel, non-aluminum, non-calcium phosphate binder, is effective and well tolerated in Hyperphosphatemia. Abstract presented at: 9th Asian Pacific Congress of Nephrology; February 16-20, 2003; Pattaya, Thailand.
25.
HutchisonA.J., Al BaajF.Safety and efficacy of lanthanum carbonate for treatment of hyperphosphataemia in haemodialysis patients over 12 months. Abstract presented at: National Kidney Foundation Clinical Meeting; April 2-6, 2003; Dallas, TX.
26.
AkehurstR., BrennanA.Assessing the potential cost effectiveness of lanthanum carbonate in the control of Hyperphosphatemia. Abstract F-PO1007 presented at: Annual Meeting of the American Society of Nephrology; October 27 – November 1, 2004; St. Louis, MO.
27.
FinnW.F., JoyM.S.The new phosphate-binding agent lanthanum carbonate: further evidence of long-term (2-year) efficacy and safety. Abstract PUB006 presented at: Annual Meeting of the American Society of Nephrology; October 27 – November 1, 2004; St. Louis, MO.
28.
FinnW.F., JoyM.S.Lanthanum carbonate (Fosrenol), a novel phosphate binder, is safe and effective in the long-term treatment of hyperphosphatemia in end-stage renal disease. Abstract presented at: 9th Asian Pacific Congress of Nephrology; February 16-20, 2003; Pattaya, Thailand.
29.
FinnW.F., JoyM.S., WebsterI., GillM.A long-term (2-year) assessment of the safety and efficacy of lanthanum carbonate, a non-calcium, non-aluminum phosphate binder, for the treatment of Hyperphosphatemia. Abstract presented at: 40th ERA-EDTA World Congress of Nephrology; June 8-12, 2003; Berlin, Germany.
30.
BehetsG.J.An assessment of the effects of lanthanum on bone in a chronic renal failure (CRF) rat model [abstract].J Am Soc Nephrol.2001; 12: A3862.
31.
BehetsG.J.Effects of the phosphate binder Renagel (sevelamer) on biochemical parameters and bone histology in a chronic renal failure (CRF) rat model. Abstract A3863 presented at: ISN/ASN World Congress of Nephrology; October 16, 2001; San Francisco.
FiddlerG., WebsterI.Lanthanum carbonate is well tolerated when administered with warfarin and has no effect on its pharmacokinetics. Abstract presented at: National Kidney Foundation Clinical Meeting; April 2-6, 2003; Dallas, TX.
34.
FiddlerG., TaubelJ.Lanthanum carbonate has no effect on the pharmacokinetics of digoxin and can be administered safety in combination. Abstract presented at: National Kidney Foundation Clinical Meeting; April 2-6, 2003; Dallas, TX.
35.
FiddlerG., TaubelJ.Lanthanum carbonate has a good safety profile following concomitant administration with metoprolol and has no clinically significant effect on its pharmacokinetics. Abstract presented at: National Kidney Foundation Clinical Meeting; April 2-6, 2003; Dallas, TX.
36.
FiddlerG., TaubelJ.Lanthanum carbonate (Fosrenol) does not affect the pharmacokinetics of digoxin or warfarin. Paper presented at: 9th Asian Pacific Congress of Nephrology; February 16-20, 2003; Pattaya, Thailand.
